Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The big drugmaker is relying heavily on one new product that likely won't be able to keep up its momentum.

Why Lilly's Near-Term Prospects Aren't Looking That Great

Shares of Eli Lilly & Co. gained 0.1% in premarket trading on Tuesday after the company said it will donate 400,000 doses of Olumiant, its rheumatoid arthritis drug that is being tested as a COVID-19 treatment for the severely ill in the U.S., to the Indian government. Lilly also said it will provide royalty-free licensing agreements to drug makers there to begin manufacturing the drug.

Lilly to donate experimental COVID-19 treatment Olumiant to India

INDIANAPOLIS, May 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will outline its newly updated Environmental, Social and Governance (ESG) strategy, highlighting its commitments in key areas during the company's Sustainability Webcast today at 10:30 am ET. In addition, Lilly has launched a new comprehensive resource to provide transparency around the company's ESG goals and progress at esg.lilly.com.

Lilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe

INDIANAPOLIS, May 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic.

Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements

Coca-Cola

These buy-and-forget investments can be pillars for your portfolio for not just years, but decades.

New Investor? Buy These 2 Rock-Solid Stalwarts for Safety and Dividends

Eli Lilly and Co. LLY said Monday that its board authorized $5 billion in share repurchases while keeping the dividend unchanged. The drug maker said the new share buyback authorization, which has no time limit, is in addition to the $1 billion left on a program initiated in 2018.

Lilly board authorizes $5 billion more in buybacks

INDIANAPOLIS, May 3, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) (the "Board") has declared a dividend for the second quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is payable on June 10, 2021 to shareholders of record at the close of business on May 14, 2021.

Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization

INDIANAPOLIS, May 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its support of Direct Relief's Fund for Health Equity (the Fund) with a $5 million commitment over the next five years. The Fund launched in March 2020 with $75 million raised against a goal of $150 million.

Lilly to Commit $5 Million to Direct Relief's Fund for Health Equity

Eli Lilly and Co (LLY) CEO David Ricks on Q1 2021 Results - Earnings Call Transcript

Tucked in its Q1 earnings release, Eli Lilly And Co (NYSE: LLY) has scrapped its plans to seek approval for mirikizumab in psoriasis. The company decided not to enter the market despite the anti-IL-23p19 antibody outperforming Novartis AG's (NYSE: NVS) Cosentyx in a Phase 3 trial last year.

Eli Lil­ly Aban­dons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications

Eli Lilly's COVID-19 monoclonal antibody treatments brought in $810.1 million in global sales in the first three months of the year, but investors remain largely lukewarm about therapies that they expect to have a short lifespan.

Lilly's COVID-19 antibody drugs are a top seller this quarter, but investors aren't that excited

Misses on both the top and bottom lines weren't the only reason the big drugmaker's first-quarter update was disappointing.

Why Investors Didn't Like Lilly's Q1 Results

Eli Lilly stock crumbled Tuesday after the pharmaceutical giant lagged Wall Street's first-quarter expectations and cut its 2021 outlook on light Covid-19 treatment sales. The post Eli Lilly Stock Crumbles As Covid Antibodies Hammer Sales, 2021 Outlook appeared first on Investor's Business Daily.

Eli Lilly Stock Crumbles As Covid Antibodies Hammer Sales, 2021 Outlook

Lilly (LLY) misses first-quarter estimates for both earnings and sales. It narrows 2021 forecast.

Eli Lilly (LLY) Q1 Earnings Miss, COVID-19 Drug Demand Low

Eli Lilly And Co (NYSE: LLY) posted weaker-than-expected first-quarter earnings and cut its forecast for full-year adjusted profit due to lower demand for its COVID-19 drugs. The company posted net income of $1.35 billion, or $1.49 a share, in the quarter, down 7% from $1.457 billion, or $1.60 a share, a year ago.

Eli Lilly Shares Drop After Missing Q1 Earnings On Lower COVID-19 Drug Demand; 2021 Guidance Lagging Consensus

Lilly (LLY) delivered earnings and revenue surprises of -11.79% and -1.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) Q1 Earnings and Revenues Miss Estimates

Eli Lilly shares slump after offering cautious guidance

Drugmaker Eli Lilly and Co posted a 7% fall in quarterly profit on Tuesday, due to higher spending on research and development of treatments including COVID-19 drugs.

Eli Lilly profit falls 7% on higher costs

INDIANAPOLIS, April 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2021. $ in millions, except per share data First Quarter % 2021 2020 Change Revenue $ 6,805.6 $ 5,859.8 16% Net Income – Reported 1,355.3 1,456.5 (7)% EPS – Reported 1.49 1.60 (7)% Net Income – Non-GAAP 1,701.9 1,471.1 16% EPS – Non-GAAP 1.87 1.61 16% Certain financial information for 2021 and 2020 is presented on both a reported and a non-GAAP basis.

Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance

Bristol-Myers

Eli Lilly and Co. (NYSE:LLY) jumped four places from last year to capture the top spot in IDEA Pharma's Pharmaceutical Innovation Index, supplanting the 2020 leader Roche (RHHBY). In the drug consulting firm's Pharmaceutical Invention Index, Bristol-Myers Squibb Co. (NYSE:BMY) climbed one place to take over the top position from AstraZeneca (NASDAQ:AZN), which dropped five places to number six.

Eli Lilly Rated Top in Innovation, Bristol-Myers Leader in Invention

Eli Lilly Rated Tops in Innovation, Bristol-Myers Leader in Invention

INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company's (NYSE: LLY) Taltz® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis. In the first one-year network meta-analysis based on area under the curve, Taltz showed numerically greater cumulative benefits on completely clear skin over one year compared to seven other biologics, as measured by Psoriasis Area Severity Index (PASI) 100.

Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis

Incyte

INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY) and Incyte's (NASDAQ:INCY) OLUMIANT® (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate to severe atopic dermatitis (AD). In one BREEZE-AD5 analysis, OLUMIANT provided concurrent improvements in the severity and extent of AD, other key symptoms and quality of life as early as one week, as measured by percent change from baseline compared to placebo.

OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses

Lilly rewarded investors by producing a five-year total return CAGR of 17.7%, surpassing both the S&P index and peer group.

Eli Lilly: Robust Pipeline And Product Portfolio To Power Market Performance

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) first-quarter sales.

News for Eli Lilly Stock (LLY)